Je. Henriksen et al., GLUCOSE PROCESSING DURING THE INTRAVENOUS GLUCOSE-TOLERANCE TEST, Metabolism, clinical and experimental, 45(5), 1996, pp. 598-605
The impact of the dynamic changes in plasma glucose and insulin levels
observed during a frequently sampled intravenous (IV) glucose toleran
ce test (FSIGT) on whole-body glucose processing and muscle glycogen m
etabolism is not known. Paired randomized FSIGTs were performed in eig
ht healthy subjects (age, 31 years; range, 28 to 35; BMI, 25.4 kg/m(2)
; range, 22.3 to 32.1), one with muscle biopsy samples and one without
. The mean time average (0- to 40- and 0- to 120-minute) insulin level
s during the test were 26.6 and 11.4 mU/l, respectively. Glucose oxida
tion increased following the IV gluclose bolus (basal 1.34 +/- 0.21 v
mean value at 0 to 120 minutes 2.09 +/- 0.22 mg/kg fat-free mass [FFM]
/min, P < .02). In contrast, fractional glucose-6-phosphate [G-6-P]) (
0.1/10 mmol/L) skeletal muscle glycogen synthase activity in muscle bi
opsies obtained before and following the IV glucose bolus (-30, 30, 60
, and 120 minutes, respectively) were unchanged (38.1% +/- 3.3%, 38.3%
+/- 2.9%, 38.1% +/- 2.3%, 35.4% +/- 2.3%, NS). Skeletal muscle glycog
en concentration decreased slightly (449 +/- 54, 439 +/- 55, and 383 /- 29, and 438 +/- 48 mmol/kg dry weight, P = .05), indicating no net
storage of glucose into glycogen during the FSIGT. G-6-P decreased (0.
77 +/- 0.08, 0.64 +/- 0.07, 0.66 +/- 0.07, and 0.54 +/- 0.04 mmol/kg d
ry weight, P < .05). Levels of the insulin-regulatable glucose transpo
rter, GLUT-4, were unchanged. Insulin sensitivity (Si), glucose effect
iveness, and insulin secretion parameters (O1 and O2) were not affecte
d by the muscle biopsy procedure. In conclusion, the FSIGT is associat
ed predominantly with increased whole body glucose oxidation with no a
pparent activation of muscle glucose storage as glycogen. Thus, the Si
measured by the FSIGT, although similar in magnitude to the clamp-der
ived parameter, represents primarily glucose oxidation, in contrast to
the euglycemic clamp, which involves glucose oxidation and storage. (
C) 1996 by W.B. Saunders Company.